Douglas E. Feldman, PhD

Dr. Feldman’s research team studies the following major topic areas:

1. Immunomodulation and immune engineering for the treatment of inflammation and fibrosis.
2. Roles of modified DNA bases in immune signaling and gene control.
2. Functional analysis of viral counter-immune systems.

Categories: Gene Control, Stem Cells, Cancer, Epigenetics, DNA modification, immune engineering, immunotherapy, fibrosis, AALD

• Harvard College, Cambridge, MA. — A.B. Magna cum laude — Biochemistry
• Stanford University, Stanford, CA. — Ph.D — Molecular Cell Biology

• Activation of NK cell-mediated protective immunity for the systemic treatment of ALD
  NIH · R21AA029741 · Sep 11, 2023 – Aug 31, 2025 · Role: Principal Investigator
• Activation of NK cell-mediated protective immunity for the systemic treatment of ALD
  NIH · 1R21AA029741-01A1 · Sep 1, 2023 – Aug 31, 2025 · Role: PI
• STING-Activating CAR-NK Cell Therapy
  US DOD CDMRP · Aug 15, 2022 – Feb 14, 2024 · Role: PI
• Engineering CAR-T for treatment of alcoholic liver disease
  NIH · R21AA027535 · Sep 20, 2019 – Aug 31, 2021 · Role: PI
• Robert E. and May R. Wright Foundation Trust
  Robert E. and May R. Wright Foundation Trust
• American Cancer Society
  American Cancer Society
• James H. Zumberge Faculty Research and Innovation Fund
  James H. Zumberge Faculty Research and Innovation Fund

• Lieber, Michael
• Machida, Keigo
• Chai, Yang
• Lenz, Heinz-Josef
• Liang, Gangning
• Tsukamoto, Hidekazu